This technique measured tumor therapy response through optical cell biomass measurements and was validated by comparing BRAFi-sensitive and BRAFi-resistant melanoma cells treated with a BRAF inhibitor (BRAFi), blocking the BRAF gene which is responsible for producing B-raf and causes approximately 50% of melanomas when mutated. Here, BRAF is linked to neoplasm.